Aquestive Therapeutics, Inc. (AQST) stock
AQSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 3/30
$3.70−0.06 (-1.60%)
Close on Nov 17, 2026Market cap $464.39MP/E –Yield –
Aquestive Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Aquestive Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was -97.5%. For fiscal 2025 it was -159.5%, against -53.5% the year before. The highest annual figure on record is -0.2% in fiscal 2017.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -159.5% | −106.0 |
| FY2024 | Dec 31, 2024 | -53.5% | −23.6 |
| FY2023 | Dec 31, 2023 | -29.9% | +58.4 |
| FY2022 | Dec 31, 2022 | -88.2% | −20.0 |
| FY2021 | Dec 31, 2021 | -68.2% | +25.3 |
| FY2020 | Dec 31, 2020 | -93.6% | +6.6 |
| FY2019 | Dec 31, 2019 | -100.1% | −27.5 |
| FY2018 | Dec 31, 2018 | -72.6% | −72.4 |
| FY2017 | Dec 31, 2017 | -0.2% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -59.5% | +54.1 |
| Q1 FY2026 | Mar 31, 2026 | -29.1% | +193.0 |
| Q4 FY2025 | Dec 31, 2025 | -221.6% | −107.2 |
| Q3 FY2025 | Sep 30, 2025 | -89.6% | −28.4 |
| Q2 FY2025 | Jun 30, 2025 | -113.6% | −113.9 |
| Q1 FY2025 | Mar 31, 2025 | -222.1% | −147.8 |
| Q4 FY2024 | Dec 31, 2024 | -114.4% | −84.8 |
| Q3 FY2024 | Sep 30, 2024 | -61.2% | −42.9 |
| Q2 FY2024 | Jun 30, 2024 | 0.3% | +32.1 |
| Q1 FY2024 | Mar 31, 2024 | -74.3% | −33.0 |
| Q4 FY2023 | Dec 31, 2023 | -29.6% | +70.7 |
| Q3 FY2023 | Sep 30, 2023 | -18.3% | +58.9 |
| Q2 FY2023 | Jun 30, 2023 | -31.8% | +64.4 |
| Q1 FY2023 | Mar 31, 2023 | -41.4% | +38.0 |
| Q4 FY2022 | Dec 31, 2022 | -100.3% | +5.0 |
| Q3 FY2022 | Sep 30, 2022 | -77.2% | −17.3 |
| Q2 FY2022 | Jun 30, 2022 | -96.2% | −53.7 |
| Q1 FY2022 | Mar 31, 2022 | -79.4% | −2.7 |
| Q4 FY2021 | Dec 31, 2021 | -105.3% | +113.5 |
| Q3 FY2021 | Sep 30, 2021 | -60.0% | +106.9 |
| Q2 FY2021 | Jun 30, 2021 | -42.5% | −44.3 |
| Q1 FY2021 | Mar 31, 2021 | -76.6% | +81.5 |
| Q4 FY2020 | Dec 31, 2020 | -218.9% | −158.5 |
| Q3 FY2020 | Sep 30, 2020 | -166.8% | −78.2 |
| Q2 FY2020 | Jun 30, 2020 | 1.8% | +169.7 |
| Q1 FY2020 | Mar 31, 2020 | -158.1% | −54.7 |
| Q4 FY2019 | Dec 31, 2019 | -60.3% | +13.1 |
| Q3 FY2019 | Sep 30, 2019 | -88.6% | −111.3 |
| Q2 FY2019 | Jun 30, 2019 | -167.9% | −108.4 |
| Q1 FY2019 | Mar 31, 2019 | -103.4% | −141.8 |
| Q4 FY2018 | Dec 31, 2018 | -73.4% | −37.0 |
| Q1 FY2018 | Mar 31, 2018 | 22.7% | – |
| Q4 FY2017 | Dec 31, 2017 | -59.5% | – |
| Q3 FY2017 | Sep 30, 2017 | 38.4% | – |
| Q2 FY2017 | Jun 30, 2017 | -36.4% | – |
See a number that looks wrong?